PharmaResearch is expanding polynucleotide skin boosters into Hungary with the launch of three REJURAN treatments designed to support different aesthetic needs. Built around PN technology, the portfolio focuses on skin regeneration and quality rather than primarily adding facial volume. REJURAN is intended for broader facial treatment, while REJURAN I targets delicate areas such as around the eyes and REJURAN S focuses on wrinkles and scars. The launch was supported by clinical education and live demonstrations for local aesthetic professionals.
For PharmaResearch, entering Hungary extends REJURAN’s presence in Europe while responding to growing interest in natural-looking aesthetic treatments with limited downtime. Providing multiple specialized formulations also allows practitioners to tailor treatment to different facial areas and patient concerns. The company’s physician training strategy can support clinical adoption and build practitioner familiarity, while expanded local distribution and clinic networks create a foundation for further European growth.
Image Credit: PharmaResearch
What Makes This Trend Stand Out
- Regenerative Aesthetics
- PN-based injectables reflect a shift from volume enhancement toward biologically oriented skin quality improvements with natural-looking outcomes.
- Targeted Skin Formulations
- Specialized treatments for eyes, scars, wrinkles, and broader facial use create opportunities for more personalized aesthetic protocols.
- Clinician-led Launches
- Education programs and live demonstrations strengthen adoption pathways for novel aesthetic products in emerging regional markets.
Sectors Adopting This
- Medical Aesthetics
- Demand for low-downtime regenerative treatments is expanding the competitive landscape beyond traditional fillers and neuromodulators.
- Dermatology
- Skin regeneration technologies provide dermatology practices with new options for treating texture, scarring, and age-related concerns.
- Pharmaceutical Distribution
- Localized clinic networks and professional training infrastructure can accelerate market entry for specialized injectable therapies.
